Mark Bronstrup has studied chemistry and obtained his PhD from the TU Berlin in 1999. He has joined Aventis in 2000 and spent a research sabbatical with S. P. Gygi at Harvard Medical School in 2003. Between 2005 and 2010, he was leading the Natural Products Science section at Sanofi Aventis in Frankfurt. Between 2010 and 2013, he was managing sections dealing with biomarkers, bioimaging & biological assays. Since December 2013, he has been Head of the Chemical Biology Department at the Helmholtz Centre for Infection Research in Braunschweig and W3 Professor at the University of Hannover. His research is focused on the discovery, characterization and optimization of novel anti-infective drugs. Mark Bronstrup has studied chemistry and obtained his PhD from the TU Berlin in 1999. He has joined Aventis in 2000 and spent a research sabbatical with S. P. Gygi at Harvard Medical School in 2003. Between 2005 and 2010, he was leading the Natural Products Science section at Sanofi Aventis in Frankfurt. Between 2010 and 2013, he was managing sections dealing with biomarkers, bioimaging & biological assays. Since December 2013, he has been Head of the Chemical Biology Department at the Helmholtz Centre for Infection Research in Braunschweig and W3 Professor at the University of Hannover. His research is focused on the discovery, characterization and optimization of novel anti-infective drugs.

Biochemistry